Pharmafile Logo
Pharmafocus logo
Advanced Search

acute myeloid leukaemia

Showing 8 posts of 23 posts found.

Experimental Novartis leukaemia and mastocytosis drug gets FDA Priority Review

November 14, 2016
Research and Development, Sales and Marketing FDA, Novartis, acute myeloid leukaemia

The US FDA has granted Priority Review status to Novartis’ experimental drug PKC412 (midostaurin) as a treatment for advanced systemic …

News
celgene_1_02

Celgene and Agios to file FDA application for “first-in-class” cancer drug

September 8, 2016
Research and Development, Sales and Marketing Celgene, FDA, NDA, acute myeloid leukaemia, agios

According to an SEC 8-K filing by Agios, the company and its partner Celgene intend to file a new drug …

News
clinical_trial_3

Celator receives FDA breakthrough therapy designation for leukaemia drug

May 20, 2016
Medical Communications, Research and Development FDA, Vyxeos, acute myeloid leukaemia, breakthrough therapy, celator

A new treatment for acute myeloid leukaemia and other blood cancers from Celator Pharmaceuticals (NASDAQ: CPXX) has been granted breakthrough …

News
novartis_pic

Novartis drug PKC412 gets Breakthrough designation for AML

February 19, 2016
Medical Communications, Research and Development FDA, Novartis, acute myeloid leukaemia

Novartis’ PKC412 (midostaurin)  has become the latest in a sequence of FDA Breakthrough Therapy designations awarded this week- bagging the …

News
Vidaza product image

Celgene’s Vidaza earns wider approval

November 2, 2015
Sales and Marketing Celgene, European Commission, Vidaza, acute myeloid leukaemia, azacitidine, leukaemia

Swiss firm Celgene has been given approval by the European Commission to extend its marketing authorisation for the cancer treatment …

News

BI leukaemia drug gains FDA breakthrough status

September 18, 2013
Research and Development, Sales and Marketing Boehringer Ingelheim, FDA, acute myeloid leukaemia, breakthrough status

News
nhs_sign

AML-related revenues to nearly triple by 2017

August 26, 2013
Medical Communications, Sales and Marketing GlobalData, acute myeloid leukaemia

News

Trial failures threaten UK biotech

February 18, 2011
Research and Development AML, AS1411, AS1413, Antisoma, Juvista, Renovo, UK biotech, acute myeloid leukaemia, anti-scarring, biotech

A number of late stage failures from British biotech firms have left a looming question mark over the future of …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026